Subnormal Estimated Glomerular Filtration Rate Strongly Predict Incident Cardiovascular Events in Type 2 Diabetic Chinese Population With Normoalbuminuria

Medicine
Yi-Ting HsiehMing-Chia Hsieh

Abstract

No study has evaluated whether subnormal estimated glomerular filtration rate (eGFR) (between 61 and 90 mL/min) and high normal albumin-creatinine ratio (ACR) (<30 mg/g) are associated with cardiovascular (CV) events and mortality in type 2 diabetic (T2DM) patients with normoalbuminuria.We observed a longitudinal cohort study of 1291 T2DM patients with normoalbuminuria who were receiving intensified multifactorial treatment from 2004 to 2008. Cox regression models were used to evaluate eGFR and ACR as the risk factors of major CV events (nonfatal myocardial infarction and stroke) and mortality.During the 4-year period, 56 patients died and 159 patients developed major CV events. We found eGFR, but not ACR, to be associated with major CV events. Compared to those with eGFR higher than 90 mL/min, patients with subnormal eGFR (HR: 3.133, 1.402-7.002, P = 0.005) were at greater risk of incident major CV events. Extremely low eGFR (<30 mL/min) was associated with mortality only in patients under 65 years old.Subnormal eGFR was a strong predictor of major CV events in diabetic patients with normoalbuminuria. Normoalbuminuric diabetic patients with subnormal eGFR may need intensive CV risk factor intervention to prevent and treat CV e...Continue Reading

References

Jul 31, 2001·JAMA : the Journal of the American Medical Association·H C GersteinUNKNOWN HOPE Study Investigators
Mar 19, 2002·Annals of Epidemiology·Robert D AbbottHelen Petrovitch
Aug 23, 2002·Journal of the American Society of Nephrology : JASN·Peter W De LeeuwUNKNOWN Systolic Hypertension in Europe (Syst-Eur) Trial Investigators
Sep 18, 2002·Kidney International·Ronald M A HenryCoen D A Stehouwer
Oct 10, 2002·Kidney International·Jonathan HimmelfarbRaymond M Hakim
Jun 26, 2003·JAMA : the Journal of the American Medical Association·Holly J KramerChi-Yuan Hsu
Jul 16, 2003·Annals of Internal Medicine·Andrew S LeveyUNKNOWN National Kidney Foundation
Oct 29, 2003·Circulation·Mark J SarnakUNKNOWN American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology,
Apr 22, 2004·Journal of the American Society of Nephrology : JASN·Daniel E WeinerMark J Sarnak
Sep 24, 2004·The New England Journal of Medicine·Alan S GoChi-yuan Hsu
Jun 3, 2005·Current Opinion in Clinical Nutrition and Metabolic Care·Kamyar Kalantar-ZadehDebbie Benner
Jun 16, 2005·Kidney International·Marcello TonelliUNKNOWN Cholesterol and Recurrent Events (CARE) Trial Investigators
Feb 3, 2006·Journal of the American Society of Nephrology : JASN·Ann M O'HareLouise C Walter
May 23, 2006·BMJ : British Medical Journal·Marcello TonelliUNKNOWN Cholesterol and Recurrent Events (CARE) Trial Investigators
Jun 6, 2006·The American Journal of Medicine·Stefan StörkMichiel L Bots
Jul 17, 2007·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Neil T RaymondRobert M Higgins
Sep 15, 2007·Journal of the American Society of Nephrology : JASN·Ann M O'HareC Seth Landefeld
Jun 27, 2008·Journal of the American Society of Nephrology : JASN·John P FormanGary C Curhan
Jul 11, 2008·Kidney International·Xin J ZhouFred G Silva
Jul 22, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Auke H BrantsmaUNKNOWN PREVEND Study Group
Dec 17, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Maura RaveraGiacomo Deferrari
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
May 16, 2009·Journal of the American Society of Nephrology : JASN·Toshiharu NinomiyaUNKNOWN ADVANCE Collaborative Group
Aug 14, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Marije van der VeldeRon T Gansevoort
Aug 20, 2010·The Journal of Clinical Endocrinology and Metabolism·Yun HuangGuang Ning
Dec 21, 2013·Diabetes Care·UNKNOWN American Diabetes Association
Feb 14, 2014·Kidney International·Chi Pang WenUNKNOWN Chronic Kidney Disease Prognosis Consortium

❮ Previous
Next ❯

Software Mentioned

XLSTAT
SAS

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.